IL287066B1 - Plasma kallikrein inhibitors and methods of using them in ocular disorders - Google Patents

Plasma kallikrein inhibitors and methods of using them in ocular disorders

Info

Publication number
IL287066B1
IL287066B1 IL287066A IL28706621A IL287066B1 IL 287066 B1 IL287066 B1 IL 287066B1 IL 287066 A IL287066 A IL 287066A IL 28706621 A IL28706621 A IL 28706621A IL 287066 B1 IL287066 B1 IL 287066B1
Authority
IL
Israel
Prior art keywords
plasma kallikrein
months
kallikrein inhibitor
disclosure
compound
Prior art date
Application number
IL287066A
Other languages
English (en)
Hebrew (he)
Other versions
IL287066A (en
Original Assignee
Biocryst Pharm Inc
Clearside Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72750647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL287066(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocryst Pharm Inc, Clearside Biomedical Inc filed Critical Biocryst Pharm Inc
Publication of IL287066A publication Critical patent/IL287066A/en
Publication of IL287066B1 publication Critical patent/IL287066B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL287066A 2019-04-08 2021-10-07 Plasma kallikrein inhibitors and methods of using them in ocular disorders IL287066B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962830802P 2019-04-08 2019-04-08
PCT/US2020/027287 WO2020210368A1 (en) 2019-04-08 2020-04-08 Plasma kallikrein inhibitors and methods of use thereof in ocular disorders

Publications (2)

Publication Number Publication Date
IL287066A IL287066A (en) 2021-12-01
IL287066B1 true IL287066B1 (en) 2026-01-01

Family

ID=72750647

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287066A IL287066B1 (en) 2019-04-08 2021-10-07 Plasma kallikrein inhibitors and methods of using them in ocular disorders

Country Status (7)

Country Link
US (1) US12589093B2 (https=)
EP (1) EP3953395B1 (https=)
JP (2) JP7668227B2 (https=)
AU (1) AU2020273154A1 (https=)
CA (1) CA3136326A1 (https=)
IL (1) IL287066B1 (https=)
WO (1) WO2020210368A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150274841A1 (en) * 2014-03-27 2015-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
US20150368359A1 (en) * 2006-03-16 2015-12-24 Dyax Corp. Compositions and methods for treating ophthalmic disorders
US20160310417A1 (en) * 2013-12-20 2016-10-27 Emory University Formulations and Methods For Targeted Ocular Delivery of Therapeutic Agents
US20180354906A1 (en) * 2014-03-07 2018-12-13 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
US20190015521A1 (en) * 2017-07-17 2019-01-17 Macregen, Inc. Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX373894B (es) * 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
JP6824876B2 (ja) * 2014-08-22 2021-02-03 バイオクライスト ファーマシューティカルズ， インコーポレイテッド アミジン誘導体組成物及びそれらの使用
CA3041058A1 (en) 2016-10-31 2018-05-03 Biocryst Pharmaceuticals, Inc. Carbamimidoylphenylcarbamoyl derivatives and pharmaceutical compositions thereof useful as kallikrein inhibithors
AU2018226872A1 (en) * 2017-03-03 2019-09-05 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150368359A1 (en) * 2006-03-16 2015-12-24 Dyax Corp. Compositions and methods for treating ophthalmic disorders
US20160310417A1 (en) * 2013-12-20 2016-10-27 Emory University Formulations and Methods For Targeted Ocular Delivery of Therapeutic Agents
US20180354906A1 (en) * 2014-03-07 2018-12-13 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
US20150274841A1 (en) * 2014-03-27 2015-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
US20190015521A1 (en) * 2017-07-17 2019-01-17 Macregen, Inc. Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases

Also Published As

Publication number Publication date
JP2025108562A (ja) 2025-07-23
US12589093B2 (en) 2026-03-31
JP7668227B2 (ja) 2025-04-24
US20220160694A1 (en) 2022-05-26
AU2020273154A1 (en) 2021-12-02
EP3953395A4 (en) 2023-01-18
EP3953395A1 (en) 2022-02-16
CA3136326A1 (en) 2020-10-15
JP2022526999A (ja) 2022-05-27
EP3953395B1 (en) 2026-05-06
IL287066A (en) 2021-12-01
WO2020210368A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
AU2004260645B2 (en) Delivery of a drug via subconjuctival or periocular delivery of a prodrug in a polymeric microparticle
CN102340991B (zh) 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
US20110274748A1 (en) CAI-Based Systems and Methods for the Localized Treatment of Ocular and Other Diseases
NZ725574A (en) Compounds for treating ophthalmic diseases and disorders
US20250213541A1 (en) Suspension compositions of multi-target inhibitors
JP7470791B2 (ja) 眼疾患の予防または治療用点眼組成物
EP3953395B1 (en) Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
CA3201534A1 (en) Compounds for treating eye diseases and disorders
EP1867334A1 (en) Method of relieving or avoiding side effect of steroid compound
US20250170143A1 (en) Methods of treating ocular fibrotic pathologies
WO2026024285A1 (en) Hydrogel formulations and methods and devices for administration of the same
TW202038928A (zh) 多目標抑製劑的懸浮液組合物
HK1221909B (zh) 视网膜脉络膜病症的抑制剂